This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Limited.
UK | March 2022 | 193547
Entresto (sacubitril/valsartan) is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
(Ref: https://www.medicines.org.uk/emc/product/5074/smpc)
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.UK/yellowcard (UK).
Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about a product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com
To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.